Contact this trialFirst, we need to learn more about you.
Checkpoint Inhibitor
Regorafenib + Nivolumab for Colorectal Cancer
Recruiting1 awardPhase 1
Tampa, Florida
This trial is testing the safety and side effects of a combination of two drugs, Regorafenib and Nivolumab, in people with metastatic colorectal cancer. Researchers want to find out if this combination can help people with a certain type of cancer, called metastatic colorectal cancer with mismatch repair (MMR) proficiency.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.